← Back to Clinical Trials
Recruiting Phase 3 NCT07241377

A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and Placebo

Trial Parameters

Condition Absorption of Omega-3
Sponsor RDC Clinical Pty Ltd
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 120
Sex ALL
Min Age 18 Years
Max Age 64 Years
Start Date 2025-10-27
Completion 2026-12
Interventions
life'sTM omega O1035DS nTGlife'sTM omega O3020DS nTGMEG-3 3323rTG

Brief Summary

This is a randomised, double-blind, parallel, placebo-controlled study in healthy adults to compare the absorption of two microalgal formulations, to a fish oil and a placebo. Participant will take their assigned study product for 6 weeks and attend the clinic for 4 visits.

Eligibility Criteria

Inclusion Criteria: 1. Written informed consent obtained before any trial related assessments are performed. 2. Healthy adult females ages 18-64 who are neither pregnant nor breastfeeding or healthy adult males ages 18-64 at the time of consent. a. Female participants of child-bearing potential (females who are post-menopausal, i.e., when there has been no menstruation for a minimum of 12 months prior to screening, are considered not to be of child-bearing potential), who are not surgically sterilized, must have a negative pregnancy test at screening and be willing to practice one of the following appropriate contraceptive methods until the last visit: i. Sexual abstinence. ii. Oral contraceptives. iii. Trans dermal patches or depot injection of a progestogen drug (starting at least 4 weeks prior to product administration). iv. Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration). v. Contracep

Related Trials